Mydriasis treatment involves medications that are used to dilate or enlarge the pupil of the eye. They are useful in relaxing and paralyzing the muscles of the iris in order to prevent the pupil from constricting during an ophthalmic examination or surgery. Mydriatic agents are helpful for ocular examinations and procedures such as funduscopy, retinoscopy, fundus photography, and glaucoma screening.

The mydriasis treatment market is estimated to be valued at USD 633.3 Mn in 2024 and is expected to reach USD 878 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Key players in the mydriasis treatment market include Novartis AG, Pfizer Inc., Bausch Health Companies Inc., Akorn Inc. among others.

Mydriatic medications primarily work by blocking the muscarinic receptors in the iris sphincter muscles, thus paralyzing the sphincter muscles and dilating the pupil. Some commonly used mydriatic agents are tropicamide, phenylephrine, cyclopentolate, and homatropine. Mydriasis Treatment Market finds widespread application in eye care settings for facilitating detailed examination of the interior structures of the eye including the retina, optic disc and blood vessels.

Key players: Key players operating in the mydriasis treatment market are Novartis AG, Pfizer Inc., Bausch Health Companies Inc., Akorn Inc. Novartis offers Tropicamide ophthalmic solution which is a muscarinic antagonist anticholinergic agent.

Growing demand: The growing number of ophthalmic surgeries and eye examinations across the globe is driving the demand for mydriasis treatment. According to the World Health Organization, at least 2.2 billion people have a near or distance vision impairment globally.

Technological advancements: Advancements in ophthalmic diagnostic and surgical equipment requiring pupil dilation are also contributing to the market growth. New generation retinal cameras, surgical microscopes and OCT devices are enhancing visualization during examinations and procedures.

Market Trends
Preference for single-use vials: There is an increasing preference for single-use vials or pre-filled syringes of mydriatic drops to avoid potential risks of cross-contamination. Major players are focusing on developing convenient single-use packaging solutions.

Combination drugs: Market players are developing fixed-dose combination mydriatic drugs containing two or more active pharmacological agents to achieve improved efficacy along with enhanced convenience.

Market Opportunities
Emerging markets: Emerging markets in Asia Pacific and Latin America owing to rising healthcare expenditure and increasing medical tourism offer lucrative opportunities for key players.

Adjunct to imaging devices: Growing adoption of advanced ophthalmic imaging modalities provides an opportunity to integrate mydriasis treatment as an adjunct.

Impact of COVID-19 on Mydriasis Treatment Market
The COVID-19 pandemic has significantly impacted the growth of mydriasis treatment market. During the initial phase of the pandemic, patients were reluctant to visit hospitals and clinics for non-emergency procedures due to the risk of virus exposure. This led to sharp decline in number of surgical procedures that require mydriasis. Manufacturing and supply chains of drugs used for mydriasis were also severely disrupted during nationwide lockdowns.

However, as the restrictions are being gradually lifted, the market is witnessing steady recovery. With adequate safety protocols in place, the number of surgeries is rising again. Key market players have strengthened their distribution networks and ramped up production capacities to meet the growing demand. Various initiatives have also been taken by governments and healthcare agencies to promote effective treatment of eye diseases requiring mydriasis. It is expected that with widespread vaccination drives, the market will return to its normal growth trajectory by 2022.

The North American region currently holds the largest share of mydriasis treatment market in terms of value. Availability of advanced healthcare infrastructure and growing geriatric population prone to eye disorders in countries like US and Canada have fueled the demand. Asia Pacific is identified as the fastest growing regional market with India and China at the forefront. Increasing affordability of eye care services alongside growing medical tourism are supporting the growth of mydriasis treatment solutions across Asia Pacific nations.

Get more insights on: Mydriasis Treatment Market

Get this Report in Japanese Language: 散瞳治療市場

Get this Report in Korean Language: 산동증 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)